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Mosaicism is increasingly recognized as a cause of developmental disorders with the
advent of next-generation sequencing (NGS). Mosaic mutations of PIK3CA have been
associated with the widest spectrum of phenotypes associated with overgrowth and
vascular malformations. We performed targeted NGS using 2 independent deep-coverage
methods that utilize molecular inversion probes and amplicon sequencing in a cohort of 241
samples from 181 individuals with brain and/or body overgrowth. We identified PIK3CA
mutations in 60 individuals. Several other individuals (n = 12) were identified separately to
have mutations in PIK3CA by clinical targeted-panel testing (n = 6), whole-exome
sequencing (n = 5), or Sanger sequencing (n = 1). Based on the clinical and molecular
features, this cohort segregated into three distinct groups: (a) severe focal overgrowth due to
low-level but highly activating (hotspot) mutations, (b) predominantly brain overgrowth and
less severe somatic overgrowth due to less-activating mutations, and (c) intermediate
phenotypes (capillary malformations with overgrowth) with intermediately activating
mutations. Sixteen of 29 PIK3CA mutations were novel. We also identified constitutional
PIK3CA mutations in 10 patients. Our molecular data, combined with review of the literature,
show that PIK3CA-related overgrowth disorders comprise a discontinuous spectrum of
disorders that correlate with the severity and distribution of mutations.
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Mosaicism is increasingly recognized as a cause of developmental disorders with the advent of 
next-generation sequencing (NGS). Mosaic mutations of PIK3CA have been associated with the 
widest spectrum of phenotypes associated with overgrowth and vascular malformations. We 
performed targeted NGS using 2 independent deep-coverage methods that utilize molecular 
inversion probes and amplicon sequencing in a cohort of 241 samples from 181 individuals with 
brain and/or body overgrowth. We identified PIK3CA mutations in 60 individuals. Several other 
individuals (n = 12) were identified separately to have mutations in PIK3CA by clinical targeted-
panel testing (n = 6), whole-exome sequencing (n = 5), or Sanger sequencing (n = 1). Based on 
the clinical and molecular features, this cohort segregated into three distinct groups: (a) severe 
focal overgrowth due to low-level but highly activating (hotspot) mutations, (b) predominantly 
brain overgrowth and less severe somatic overgrowth due to less-activating mutations, and (c) 
intermediate phenotypes (capillary malformations with overgrowth) with intermediately activating 
mutations. Sixteen of 29 PIK3CA mutations were novel. We also identified constitutional PIK3CA 
mutations in 10 patients. Our molecular data, combined with review of the literature, show that 
PIK3CA-related overgrowth disorders comprise a discontinuous spectrum of disorders that correlate 
with the severity and distribution of mutations.
Introduction
Mosaicism refers to a biological phenomenon in which an individual derived from a single fertilized egg 
has two or more populations of  cells with different genotypes. This process can be the result of  spontaneous 
mutations occurring at different times during the life course of  a multicellular organism, and is a widespread 
phenomenon during the normal aging process (1). Here, we will refer to somatic mosaicism as a process 
occurring strictly during development (postzygotically), excluding mosaicism confined to germ cells (germ-
line mosaicism) and somatic mosaicism associated with cancer (2). While this phenomenon has been known 
for many years, the association of  mosaic mutations with human disease began with discovery of  mosaic 
chromosomal disorders, and patchy (or segmental) manifestations of  Mendelian disorders (3, 4). The first 
sequencing-based proof  of  mosaic aberrations came in 1991 with discovery of  activating mutations of  the 
GNAS gene in McCune-Albright syndrome (5, 6). Subsequently, an increasing number of  other conditions, 
largely congenital or childhood-onset developmental disorders, have been associated with mosaic mutations. 
Examples include Proteus syndrome (AKT1), Sturge-Weber syndrome (GNAQ), neurocutaneous melanosis 
(NRAS), epidermal nevi and linear nevus sebaceous syndrome (HRAS, KRAS, PIK3CA), Maffuci and Ollier 
syndromes (IDH1, IDH2), and encephalocraniocutaneous lipomatosis (FGFR1); disorders first proposed to 
be mosaic based on their asymmetric, patchy presentation, and lack of  familial recurrence (7, 8). Mosaic 
mutations of  these genes were primarily identified with the advent of  massively parallel or next-generation 
sequencing (NGS) methods that facilitate detection of  low-frequency variation, especially in affected tissues.
However, there are several limitations in our knowledge of  mosaic developmental disorders, particular-
ly which molecular diagnostic methods are best, which tissues should be assayed, and the nature and rela-
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tionship between phenotypes and genotypes. The low-level mosaicism found in these disorders poses sig-
nificant challenges to conventional clinical diagnostic approaches. Current molecular methods in standard 
clinical laboratories rely on Sanger sequencing for single-gene analysis, and standard-depth NGS methods 
including targeted panels or whole-exome sequencing (with many clinical diagnostic labs using 20× to 30× 
as the minimum depth of  coverage for putatively constitutional or germline disorders) (9). However, these 
methods are not sensitive enough to detect low-level mutations, particularly when the level of  mosaicism 
is very low (<5%–10%) in the tissue from which DNA is isolated (typically peripheral blood lymphocytes).
Of the genes associated with mosaicism in developmental disorders, mutations of  PIK3CA have been asso-
ciated with the widest spectrum of developmental phenotypes to date, with most described as distinct clinical 
entities long before the link to PIK3CA was discovered (10). PIK3CA encodes the alpha catalytic subunit of  
phosphatidylinositol-4,5-bisphosphate 3-kinase, a central member of  the phosphatidylinositol 3-kinase (PI3K) 
enzyme family (11). PIK3CA functions as an oncogene, and activating (or gain-of-function) mutations of  
PIK3CA are widely seen in human cancers (12, 13). The most common PIK3CA mutations are p.Glu542Lys, 
p.Glu545Lys, and p.His1047Arg, which are seen in ~80% of somatic tissues in cancer (and therefore termed 
“hotspot” mutations). Based on their degree of  activity, several other classes of  PIK3CA mutations have been 
described including strong, intermediate, and weak (13). Some of  these same gain-of-function PIK3CA muta-
tions have been recently reported in a range of  pediatric developmental phenotypes. These disorders are 
broadly characterized by cutaneous vascular malformations 
with segmental overgrowth and involve multiple tissues or 
body regions. These conditions have been variably classified 
as Klippel-Trenaunay (KTS), congenital lipomatosis with 
overgrowth, vascular malformations, epidermal nevi, and 
skeletal/scoliosis/spinal abnormalities (CLOVES), mega-
lencephaly-capillary malformation syndrome (MCAP), and 
dysplastic megalencephaly (DMEG), but the spectrum and 
differences between these disorders have not been defined.
Table 1. Cohort of children with brain and/or body overgrowth screened for PIK3CA mutations
CohortA MCAP MEG Somatic overgrowthC
Sequencing method smMIPs/MIPs smMIPs smMIPs
Number of patients 131 19 31
Number of samples 174 36 31
Number of mutation-positive patients (%) 50 (38.2%) 5 (26.3%)B 9 (29.1%)
Number of mutation-negative patients (%) 81 (61.8%) 14 (73.7%) 22 (70.9%)
Number of samples in each cohort
Blood samples 72 12 6
Saliva samples 71 19 8
Skin samples 15 3 10
Other samples 16 2 7
Abbreviations: MCAP, megalencephaly-capillary malformation syndrome; MEG, megalencephaly; MIPs, molecular inversion probes; smMIPs, single-
molecule molecular inversion probes. Notes: APatients identified by other methods including whole-exome sequencing (n = 5), targeted NGS (n = 6), and 
Sanger sequencing (n = 1) are excluded from this table. BThis cohort includes patients with mutations in other genes including 2 AKT3 mutation–positive 
patients, 1 MTOR mutation–positive patient, and 1 PTEN mutation–positive patient. These individuals are not reported in this study. CIncluding patients 
with features of CLOVES, KTS, CMO, and other forms of overgrowth with vascular malformations. 
 
Figure 1. Levels of mosaicism in PIK3CA by sample type. Dot 
blot graph showing alternative allele percentages (AAPs) clus-
tered by type of tissue in all mutation-positive individuals (n = 
72). Horizontal bars indicate the mean AAP within each sample 
type: red = blood (n = 44); blue = saliva (n = 38); orange = skin 
fibroblasts (n = 26). Two-tailed t test (P values): blood-saliva: P = 
0.035; blood-skin: P = 0.036; saliva-skin, P = 0.65.
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Here, we report the largest series of  patients to date with developmental disorders associated with 
PIK3CA mutations, identified using 2 orthogonal deep-targeted NGS methods that utilize molecular inver-
sion probes (MIPs) and amplicon sequencing, to determine the mutational spectrum and quantify mutation 
levels in multiple tissues from affected individuals. By combining our data with previous reports, we assess 
available clinical molecular diagnostic methods, the most ideal tissue samples to be assayed, and derive gen-
otype-phenotype correlations in this spectrum of  disorders. We show that the phenotypes are not simply 
related to the level and distribution of  PIK3CA mutations, but also to the class of  mutation. Specifically, we 
show that CLOVES and KTS, as well as most localized lesions, are caused by one of  the three most com-
mon oncogenic (“hotspot”) mutations or occasionally by strong or intermediate mutations, while MCAP is 
caused largely by a different set of  less-activating mutations, with a much wider mutational spectrum that 
overlaps at only a few strong mutations (13). We also show that mutations are not equally detectable from 
apparently unaffected but easily available “surrogate” tissues, with levels of  mosaicism on average lower in 
peripheral blood lymphocytes than saliva, and lower in saliva than skin fibroblasts.
Results
We screened a cohort of  241 DNA samples from 181 individuals with brain and body overgrowth for 
mutations in the PIK3CA gene using two deep NGS methods that utilize MIPs (14, 15) and amplicon 
sequencing. This cohort included 131 individuals with features of  MCAP, 19 with diffuse brain over-
growth or megalencephaly, and 31 with various forms of  somatic overgrowth and vascular malforma-
tions including CLOVES, KTS, and capillary malformations with overgrowth (Table 1 and Supplemental 
Figure 1; supplemental material available online with this article; doi:10.1172/jci.insight.87623DS1). We 
identified mutations of  PIK3CA in 60 individuals (33%). Several other patients (n = 12) were identified to 
have mutations separately by clinical targeted-panel testing (n = 6), clinical whole-exome sequencing (n = 
5), or Sanger sequencing (n = 1), and were included to highlight the clinical and molecular variability of  
this spectrum of  disorders. This cohort includes one of  our previously published MCAP patients, as we 
have analyzed several newly acquired tissue samples from this patient in this study (16). The remaining 23 
patients with MCAP who were previously published were excluded from this study (16). The mutations 
identified, levels of  mosaicism, and tissue distribution in this cohort are listed in Tables 2, 3, and 4. The 
levels of  mosaicism in all tissues of  all mutation-positive patients and their parents using all molecular 
methods are listed in Supplemental Table 1.
Molecular results
Levels of  mosaicism and tissue distribution. We identified 29 mutations of  PIK3CA, including 16 novel muta-
tions that have not been previously identified in developmental disorders, to our knowledge. Oncogenic 
mutations at all of  these amino acid residues were present in the Catalogue of  Somatic Mutations in Can-
cer (COSMIC; http://cancer.sanger.ac.uk/cosmic). None of  the mutations were present in public data-
bases including the 1000 Genomes project (http://www.1000genomes.org), the NHLBI Exome Variant 
Server (http://evs.gs.washington.edu/EVS), or the Exome Aggregation Consortium (ExAC; http://exac.
broadinstitute.org), with the exception of  p.Glu545Lys and p.His1047Arg, which were present at very low 
frequencies in ExAC (<0.0001). Alternative allele percentages (the percentage of  alternate or mutant reads 
to total reads; AAP) ranged from 1% to 59.5% across the entire cohort (Tables 2, 3, and 4 ). We observed 
substantial variation in AAPs in multiple samples from the same individual, with levels of  mosaicism 
in blood (peripheral lymphocytes) ranging from undetectable to 59.5% (mean AAP 16.5%; 43 samples), 
saliva (lymphocytes and epithelial cells) from undetectable to 54% (mean AAP 24%; 37 samples), and 
skin-derived fibroblasts from 4% to 60% (mean AAP 26.4%; 20 samples). The AAPs grouped by sample 
type (blood, saliva, skin fibroblasts) are shown in Figure 1, whereas the AAPs for each sample type in all 
mutation-positive individuals are shown in Supplemental Figure 2. For a few individuals, we tested addi-
tional sample types including buccal swabs (n = 4 samples), surgically resected tonsils (lymphoid tissue; n = 
2), and occipital bone dura mater removed during posterior fossa decompression surgery (n = 1).
Diagnostic testing methods. The average coverage of  single-molecule MIPs (smMIPs) was 450.74×, with 
an average of  71.27% of  coding regions covered by 50 or more capture events, and with 2% being the lower 
threshold of  mutant allele detection. All amino acid residues in which mutations were previously identified 
were well covered by smMIPs in the entire cohort (Supplemental Figure 3). All mutations identified via 
smMIPs were confirmed using a second orthogonal method (amplicon sequencing), when sufficient DNA 
5insight.jci.org   doi:10.1172/jci.insight.87623
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was available. Amplicon sequencing yielded high coverage data for all mutations, with a mean coverage of  
1975×. None of  these mutations were present in the parents of  affected individuals by amplicon sequenc-
ing. Overall, AAPs detected by amplicon sequencing were similar to smMIP results, although the latter 
were usually slightly higher for the same samples (Supplemental Figure 4). This may be partly due to allelic 
bias/preferential amplification of  amplicon sequencing when compared to smMIPs.
Clinical testing identified several more patients with PIK3CA mutations. Mutations in 6 individuals were 
detected by targeted NGS using the Agilent SureSelect Capture technology. Another 5 were identified using 
standard-depth whole-exome sequencing (WES) on blood-derived DNA, and 1 patient was identified to 
have a mutation by standard Sanger sequencing. AAPs in these samples ranged from 41%–59.5%, suggesting 
constitutional mutations, with the exception of  1 patient (LR15-238) found to have the p.Arg93Gln mutation 
Table 2. PIK3CA mutations and levels of mosaicism — part 1 (n = 22 patients) [PIK3CA: NM_006218.2]
Sample # Diagnosis Position cDNA change Amino acid 
change
Alternative/total alleles (% alt alleles) N 
COSMIC
INH TypeD
Blood Saliva FB Other 
tissues
PI3K-ABD (AA 16–105) n = 4
LR14-323C MCAP 3:178916891 c.278G>A p.Arg93GlnA  47%SS ~50%Sanger – – 14 De novo Const.
LR15-238 OVG 3:178916891 c.278G>A p.Arg93GlnA 19%WES – – – 14 De novo Mosaic
LR01-060B,C MCAP 3:178916924 c.311C>T p.Pro104LeuA – 41%MIPs 49%MIPs – 5 De novo Presumed 
Const.
LR13-359 MCAP 3:178916924 c.311C>T p.Pro104LeuA 11%MIPs 42%MIPs – – 5 De novo Mosaic
C2 membrane (AA 330–487) n = 18
LR15-076C MEG 3: 178921548 c.1030G>A p.Val344MetA 41.5%WES – – – 13 De novo Const.
LR12-365 MCAP 3:178921552 c.1034A>C p.Asn345ThrA – 39%MIPs – – 3 Mother 
negative
Presumed 
Const.
LR11-076 MCAP 3:178921566 c.1048G>A p.Asp350AsnA 12%Amp 32%MIPs – 10%LB,Amp 3 De novo Mosaic
LR13-036C MEG-
macrosomia
3:178922324 c.1093G>A p.Glu365LysA 52%WES – – – 10 De novo Const.
LR13-264 MCAP 3:178922324 c.1093G>A p.Glu365LysA 2%SS – 29%SS – 10 NA Mosaic
LR11-374 MCAP 3:178922364 c.1133G>A p.Cys378Tyr 3%MIPs 40%MIPs – – 2 De novo Mosaic
LR11-418 MCAP 3:178922364 c.1133G>A p.Cys378Tyr 2%MIPs – – – 2 Mother 
negative
Mosaic
LR12-131 OVG 3:178922364 c.1133G>A p.Cys378Tyr 7%MIPs – ds– – 2 De novo Mosaic
LR13-328 MCAP 3:178922364 c.1133G>A p.Cys378Tyr – – – 29%BS, 
MIPs
2 De novo Mosaic
LR12-382B MCAP 3:178922364 c.1133G>A p.Cys378Tyr – 7%MIPs – – 2 De novo Mosaic
LR14-278C MCAP 3: 178922364 c.1133G>A p.Cys378Tyr  ~50%WES – – – 2 De novo Const.
LR11-200 MCAP 3:178928067 c.1345C>A p.Pro449ThrA – – 37%MIPs – 4 NA Mosaic
LR14-358C MCAP 3:178928067 c.1345C>A p.Pro449ThrA ~50%Sanger – – – 4 De novo Const.
LR11-392 MCAP 3:178928079 c.1357G>A p.Glu453LysA 2%MIPs – – – 25 NA Mosaic
LR12-070 OVG-MD 3:178928079 c.1357G>A p.Glu453LysA – 0%MIPs 25%MIPs – 25 NA Mosaic
LR12-184 OVG 3:178928079 c.1357G>A p.Glu453LysA 1%Amp, 1%SS 24%MIPs 5%–17%several 
skin samples, Amp 
19%SS
– 25 De novo Mosaic
LR12-329 OVG-MD 3:178928079 c.1357G>A p.Glu453LysA – 6%MIPs – – 25 Mosaic
LR13- 
048 B,C
MCAP 3:178928078 c.1359_1361delAGA p.Glu453del 45%MIPs – – – 1 Mother 
negative
Const.
Abbreviations: ABD, adaptor-binding domain; Amp, amplicon sequencing; BS, buccal swab; FB, skin-derived fibroblasts; INH, inheritance; LB, 
lymphoblastoid cell line; MEG, megalencephaly; MCAP, megalencephaly-capillary malformation syndrome; MD, macrodactyly; MIPs, molecular inversion 
probes; NA, unavailable; OVG, overgrowth; Sanger, Sanger sequencing; SS, Agilent SureSelect; WES, whole-exome sequencing. Protein domains are 
adapted from: http://www.uniprot.org/uniprot/P42336#family_and_domains. (13). Notes: ANovel PIK3CA mutations. BExpanded or newly-published 
molecular results on previously published patients: LR01-060 (patient 3) (57), LR12-382 (patient 7) (59), and LR13-048 (patient 1) (60). CConstitutional 
or apparently constitutional mutations. DMutations were assigned conservatively constitutional when AAP was greater than 35% in blood (lymphocyte-
derived) DNA. Mutations with AAPs less than 35%, particularly in several tissue samples, were assigned as mosaic. Mutations were presumed to be 
constitutional when the AAP was greater than 35% in nonblood-derived DNA (particularly saliva). The numbers of COSMIC mutations are based on those 
present when the COSMIC database was last accessed in May 2016.
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in 30 of  159 reads (19%). AAPs in the 6 patients tested by targeted NGS ranged from 1%–47%. In 2 patients 
(LR14-323, LR15-227), AAPs were 47% in blood-derived DNA, again suggesting constitutional mutations.
Overall, we identified 29 PIK3CA mutations in 72 individuals. We also reviewed published data on 
PIK3CA mutations in developmental pediatric disorders (all phenotypes except for cancer; Figure 2) (16–
29). When added to our data, we find that all developmental phenotypes combined have been associated 
Table 4. PIK3CA mutations and levels of mosaicism — part 3 (n = 31 patients) [PIK3CA: NM_006218.2]
Sample # Diagnosis Position cDNA 
change
Amino acid change Alternative/total alleles (% alt alleles) N 
COSMIC
INH TypeD
Kinase domain (AA 797–1068) n = 31
LR13-045 OVG 3:178947865 c.2740G>A p.Gly914Arg – 0%MIPs 15%MIPs, 
5%FB-normal, MIPs
– 1 De novo Mosaic
LR13-038 MCAP 3:178947865 c.2740G>A p.Gly914Arg 3%MIPs –  46%MIPs – 1 De novo Mosaic
LR13-050B MCAP 3:178947865 c.2740G>A p.Gly914Arg 7%MIPs 18%MIPs – – 1 De novo Mosaic
LR12-130 MCAP 3:178947865 c.2740G>A p.Gly914Arg – 19%MIPs – – 1 De novo Mosaic
LR12-327 MCAP 3:178947865 c.2740G>A p.Gly914Arg – 6%MIPs – – 1 Mother 
negative
Mosaic
LR12-343 MCAP 3:178947865 c.2740G>A p.Gly914Arg 30%Amp 54%MIPs – – 1 De novo Mosaic
LR12-383 MCAP 3:178947865 c.2740G>A p.Gly914Arg – 21%MIPs – – 1 De novo Mosaic
LR13-047 MCAP 3:178947865 c.2740G>A p.Gly914Arg 11%MIPs – – – 1 NA Mosaic
LR11-382 MCAP 3:178947865 c.2740G>A p.Gly914Arg 2%MIPs – – – 1 NA Mosaic
LR15-337 MCAP 3:178947865 c.2740G>A p.Gly914Arg 6%SS – 10%SS – 1 NA Mosaic
LR13-294 MCAP 3:178948044 c.2816A>G p.Asp939GlyA 32%MIPs – – – 7 De novo Mosaic
LR12-340C OVG 3:178948100 c.2872C>A p.Gln958LysA – 45%MIPs – – 0E De novo Presumed 
Const.
LR06-337B MCAP 3:178948136 c.2908G>A p.Glu970LysA 19%MIPs – – 16%LB, MIPs 5 De novo Mosaic
LR13-108 MCAP 3:178952006 c.3061T>C p.Tyr1021HisA – 40%MIPs – – 4 De novo Presumed 
Const.
LR11-081 MCAP 3:178952018 c.3073A>G p.Thr1025Ala – – 39%SS – 31 NA Presumed 
mosaic
LR13-169 MCAP 3:178952048 c.3103G>A p.Ala1035ThrA – 23%MIPs – – 3 De novo Mosaic
LR12-462 MCAP 3:178952048 c.3103G>A p.Ala1035ThrA – – 54%MIPs – 3 De novo Presumed 
mosaic
LR12-486 OVG 3:178952049 c.3104C>T p.Ala1035Val – – 27%MIPs – 4 De novo Mosaic
LR12-328 MCAP 3:178952074 c.3129G>T p.Met1043Ile – 16%MIPs – – 69 De novo Mosaic
LR12-203 MCAP 3:178952074 c.3129G>T p.Met1043Ile 7%MIPs 11%MIPs – – 69 De novo Mosaic
LR15-043 MCAP 3:178952074 c.3129G>T p.Met1043Ile – – 30%SS – 69 NA Mosaic
LR06-336 MCAP 3:178952074 c.3129G>T p.Met1043Ile 3%MIPs – – – 69 NA Mosaic
LR11-039 MCAP 3:178952074 c.3129G>T p.Met1043Ile 3%MIPs 12%MIPs – – 69 De novo Mosaic
LR12-010 MCAP 3:178952074 c.3129G>T p.Met1043Ile 13%MIPs – 29%MIPs – 69 De novo Mosaic
LR14-300 MCAP 3: 178952084 c.3139C>T p.His1047Tyr 2%SS – 60%SS – 68 NA Mosaic
LR11-285B MCAP 3:178952084 c.3139C>T p.His1047Tyr 4%MIPs 25%MIPs – 1%Occipital 
bone, MIPs
68 De novo Mosaic
LR13-172 MCAP-MD 3:178952085 c.3140A>G p.His1047Arg 1%MIPs – – – 1880 NA Mosaic
LR13-265B OVG-CLOVES 3:178952085 c.3140A>G p.His1047Arg 0%MIPs – 4%MIPs – 1880 NA Mosaic
LR06-340 MCAP 3:178952090 c.3145G>A p.Gly1049Ser – – – 4%LB, MIPs 24 NA Mosaic
LR12-089 MCAP 3:178952152 c.3207A>G p.stop1069Trpext*4A 22%MIPs 37%MIPs – – 7 De novo Mosaic
LR11-446 MCAP 3:178952152 c.3207A>G p.stop1069Trpext*4A – 22%MIPs – – 7 De novo Mosaic
Abbreviations: Amp, amplicon sequencing; CLOVES, congenital lipomatous truncal overgrowth, vascular anomalies, epidermal nevi and skeletal/spinal 
anomalies; FB; skin-derived fibroblasts; INH, inheritance; LB, lymphoblastoid cell line; MCAP, megalencephaly-capillary malformation syndrome; MD, 
macrodactyly; MIPs, molecular inversion probes; NA, unavailable; OVG, overgrowth; SS, Agilent SureSelect. Protein domains are adapted from: http://
www.uniprot.org/uniprot/P42336#family_and_domains. Notes: Mutations classified as cancer hotspot mutations (most activating) are highlighted 
in red, intermediate mutations are highlighted in blue (13). ANovel PIK3CA mutations. BExpanded or newly published molecular results on previously 
published patients: LR13-050 (patient 2) (60), LR06-337 (patient 14) (31), and LR11-285 (16). CConstitutional or apparently constitutional mutations. 
In patients LR13-108 and LR12-462, blood-derived DNA was not available for analysis, therefore, the possibility of mosaicism cannot be conclusively 
excluded. DMutations were assigned constitutional when the AAP was greater than 35% in blood (lymphocyte-derived) DNA. Mutations with AAPs less 
than 35%, particularly in several tissue samples, were assigned as mosaic. Mutations were presumed to be constitutional when the AAP was greater 
than 35% in nonblood-derived DNA (particularly saliva). EOther mutations at this site have been seen in COSMIC. The numbers of COSMIC mutations are 
based on those present when the COSMIC database was last accessed in May 2016.
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with 41 different PIK3CA mutations involving 33 codons and include 27 recurrent mutations (i.e., seen in 
more than one affected individual). The three hotspot PIK3CA mutations (p.Glu542Lys, p.Glu545Lys, and 
p.His1047Arg) are highly recurrent (i.e., seen frequently) in pediatric disorders. We found that two “non-
hotspot mutations” (p.Glu726Lys and p.Gly914Arg) are also highly recurrent in developmental pheno-
types, having now been detected in more than 10 patients each.
Most of  these mutations are proven or predicted to have a gain-of-function (GOF) mechanism, and 
oncogenic mutations at all of  these amino acid sites have been seen in COSMIC (13). Published func-
tional studies demonstrate a GOF mechanism for at least 9 of  41 mutations. For another 8 mutations, 
GOF has been shown for different missense mutations at the same codon (13). For example, our study 
identified p.Asn345Thr, p.Glu545Asp, and p.Gln546His mutations, while GOF has been shown for 
p.Asn345Lys, p.Glu545Lys, p.Glu545Gly, p.Gln546Lys, and p.Gln546Pro. We also detected p.Tyr1021His 
and p.Ala1035Thr mutations in our series, while p.Tyr1021Cys and p.Ala1035Val mutations have been 
found in other patients (16). Further, Glu545Ala and Glu545Lys mutations have been previously detected 
in individuals with undefined “Cowden-like” features as well (30).
Clinical results
The clinical features of  all mutation-positive individuals are listed in Supplemental Tables 2 and 3. Clinical 
photographs and brain MRI images of  some of  these individuals are shown in Figures 3–5. Based on clini-
cal and molecular characteristics, these patients can be segregated into three groups, as follows.
Figure 2. Distribution of PIK3CA mutations by functional domain in cancer and developmental (pediatric) disorders. Graph showing the number of pub-
lished PIK3CA mutations by amino acid location in the Catalogue of Somatic Mutations in Cancer (COSMIC) database of somatic variation in cancer (shown 
in green; last accessed May 2016) and in children with developmental disorders comparing the megalencephaly-capillary malformation syndrome (MCAP; 
shown in blue) and all other developmental disorders (shown in orange). Mutations shown include those reported in this study as well as published 
mutations. Notes: (a) The 2-tailed P value by Fisher’s exact test was less than 0.0001, supporting that the association between MCAP and non-hotspot 
mutations and non-MCAP and hotspot associations is extremely statistically significant. (b) “Hotspot” mutations in this analysis are the most activating 
mutations in somatic tissues in cancer (p.Glu542Lys, p.Glu545Lys, p.His1047Arg) (13).
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Group 1: MCAP syndrome. Most individuals with mosaic PIK3CA mutations in our cohort (n = 50) had 
classic features of  MCAP, characterized by brain overgrowth (megalencephaly) and cutaneous vascular 
malformations, with variable body overgrowth, connective tissue laxity, and digital anomalies (polydactyly 
and syndactyly) (Figure 3) (31, 32). Several of  our MCAP patients had additional noteworthy clinical find-
ings including (a) complex structural heart defects or arrhythmias (n = 12), (b) lymphatic malformations 
including chylothorax and lymphedema (n = 5), (c) predisposition to thrombosis (n = 3), (d) endocrine dis-
orders including hypothyroidism (n = 3), growth hormone deficiency (n = 2), and rhizomelic shortening of  
the extremities (n = 3). Six patients had episodes of  hypoglycemia (Supplemental Tables 2 and 3). Interest-
ingly, several of  our MCAP patients (n = 6) had constitutional (or apparently constitutional) mutations in 
PIK3CA (including LR14-323, LR14-278, LR14-358, LR13-048, LR15-227, and LR15-246). Two of  these 
patients (LR15-227 and LR15-246) had the p.Glu726Lys mutation.
Group 2: intermediate phenotypes — capillary malformations with overgrowth and lipomatosis (CMO, CMOL). 
Several patients (n = 7) had novel phenotypes with features either overlapping MCAP but lacking megalen-
cephaly or suggesting a milder variant of  CLOVES. Patient LR15-238 had mild somatic hemihypertrophy 
and cutaneous vascular malformations (facial capillary malformation, and reticulated diffuse capillary mal-
formations on the body), but was normocephalic. She had perinatal bradycardia, transient dilated cardiomy-
opathy, and a history of  possible nonocclusive venous thrombosis in the internal jugular vein of  unknown 
etiology. She had the p.Arg93Gln mutation in 19% of  alleles in peripheral blood lymphocytes. Interestingly, 
the same mutation was identified in another patient with classic features of  MCAP (LR14-323). The muta-
tion in the latter patient appeared to be constitutional, seen in ~50% of  alleles in blood- and saliva-derived 
DNA. Patient LR11-082 had congenital onset somatic overgrowth, diffuse congenital livedo reticularis and 
syndactyly, as well as severe joint laxity and multiple joint dislocations (Figure 4, A–D). She was normoce-
phalic, and brain MRIs performed at 5 days and 6 months of  age showed no cortical malformation. Inter-
estingly, she had progressive cerebellar tonsillar ectopia and a markedly large cerebellum on her MRI at 6 
months (Figure 5, A and B). This patient harbored the p.Gly106Val mutation in 34% and 40% of  alleles in 
blood and skin, respectively. Patient LR12-131 had hemihypertrophy, capillary malformation on the phil-
trum and midline lower lip, a capillary malformation on the right arm, and toe syndactyly, but lacked other 
classic features of  MCAP. He had a mosaic p.Cys378Tyr mutation in 7% of  alleles in blood-derived DNA.
Patient LR12-070 had congenital hemihypertrophy, epidermal nevi, and lipomatous overgrowth of  the 
trunk that was characteristically milder than CLOVES (Figure 4, E–G). He also had overlying capillary mal-
formations, and macrodactyly requiring surgical excision. He harbored the p.Glu453Lys mutation in 25% 
of  alleles in fibroblasts. This mutation was undetectable in saliva. Patient LR12-184 had diffuse asymmetric 
somatic overgrowth, reticulated port-wine stain, syndactyly, and connective tissue laxity. He was normo-
cephalic, with no cortical malformations, and normal cognition. Interestingly, his brain MRI scan at age 2 
months showed severe cerebellar tonsillar ectopia (Figure 5C). He subsequently developed sporadic swelling 
of  the neck believed to be due to lymphatic fluid accumulation. He harbored the p.Glu453Lys mutation at 
variable levels (ranging from 5%–17% of  alleles in affected skin regions, 24.5% in saliva, and 0.9% of  alleles 
in blood-derived DNA). Patient LR12-329 had hemihypertrophy, cutaneous vascular malformations, and 
multiple cutaneous lipomas, but lacked classic features of  MCAP or CLOVES. He had the p.Glu453Lys 
mutation in 6% of  alleles in saliva. Patient LR13-045 also had hemihypertrophy and diffuse congenital live-
Figure 3. Clinical photographs of MCAP patients. (A) Facial photograph of patient LR14-323 (p.Arg83Gln). (B–D) Photograph of the face (B), occipital 
region (C), and left foot (D) of LR13-359 (p.Pro104Leu) showing MEG, occipital capillary malformation, and syndactyly of the second, third, and fourth 
toes. (E) Computed tomography (CT) image of LR01-060 (p.Pro104Leu) showing the subcutaneous hemangioma (arrowheads). (F) Photograph of 
the trunk of LR12-080 (p.Arg115Pro) showing cutaneous capillary malformation with midline delineation. (G) Photograph of LR12-365 (p.Asn345Thr) 
showing diffuse capillary malformations, MEG with a prominent forehead, and postaxial polydactyly of the left hand. (H) Photograph of LR13-036 
(p.Glu365Lys) showing MEG, a disproportionately small body, and short extremities (clinically diagnosed with rhizomelic shortening of the extremities). 
(I) Photograph of LR11-418 (p.Cys378Tyr) showing diffuse capillary malformations and apparent megalencephaly (MEG). (J and K) Photograph of the 
face (J) and left foot (K) of LR12-330 (p.Glu545Asp) showing clear MEG, capillary malformation of the philtrum, skin laxity of the forehead, and syn-
dactyly of the second, third, and fourth toes. (L and M) Photographs of the face (L) and body (M) of LR13-038 (p.Gly914Arg) showing MEG, reticulated 
capillary malformations, pigmented nevus of the right arm, and asymmetry of the legs. (N and O) Photographs of the chest (N) and lower extremity 
(O) of LR12-383 (p.Gly914Arg) showing clear asymmetry of the trunk involving the right breast and overgrowth of the right leg with prominent venous 
network. (P and Q) photographs of the left (P) and right (Q) feet of LR11-081 (p.Thr1025Ala) showing bilateral asymmetric macrodactyly, sandal-gap 
toes, and capillary malformations. (R) Photograph of the feet of LR13-169 (p.Ala1035Thr) showing syndactyly of the second, third, and fourth toes on 
the right, and second and third toes on the left. (S and T) photographs of the face (S) and lower extremities (T) of LR12-328 (p.Met1043Ile) showing 
facial and body asymmetry, MEG with a prominent forehead, and capillary malformations on the face and body.
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do reticularis but lacked megalencephaly. 
He had the p.Gly914Arg mutation in 5% 
and 15% of  alleles in normal and affected 
skin-derived fibroblasts, respectively. This 
mutation was undetectable in saliva-
derived DNA.
Group 3: hotspot-associated phenotypes 
(CLOVES/DMEG). Four patients harbored 
hotspot PIK3CA mutations most common-
ly seen in cancer. Two of  these patients had 
a mosaic p.Glu542Lys mutation. Patient 
LR12-183 had a novel constellation of  
features including megalencephaly with 
diffuse cortical dysplasia, partial agenesis 
of  the corpus callosum, dysplasia/hypo-
plasia of  the cerebellar vermis and hemi-
spheres, diffuse dysmyelination, abnormal 
high T2 signal intensities in the red nuclei 
and thalami bilaterally, and a very large 
tectum (Figure 5, D–G). He also had mul-
tiple linear sebaceous nevi on the face and 
trunk (Figure 4, H and I). This combina-
tion of  features meets criteria for linear 
nevus sebaceous or Schimmelpenning 
syndrome (33–35). This patient’s muta-
tion was seen in 39/139 (28%) of  alleles 
in saliva-derived DNA. Patient LR13-197 
had diffuse megalencephaly with bilateral 
cortical dysplasia, hippocampal dysplasia, 
white matter dysmyelination, and dysplas-
tic ventricles bilaterally (Figure 5, H and 
I). She harbored the p.Glu545Lys muta-
tion at 26% of  alleles in saliva-derived DNA. Patients LR13-172 and LR13-265 both had very low-level 
mosaic p.His1047Arg mutations. Patient LR13-172 had megalencephaly with macrodactyly and harbored 
the mutation in 1% of  alleles in blood-derived DNA (Figure 4, J and K). Patient LR13-265 had features of  
CLOVES syndrome with lipomatous overgrowth involving the face and trunk, prominent venous network 
in the abdominal wall, verrucous overgrowth of  the trunk, and macrodactyly. His mutation was present in 
4% of  affected skin-derived DNA, and absent from several unaffected skin samples. We also obtained addi-
Figure 4. Clinical photographs of PIK3CA 
mutation–positive patients with segmental 
overgrowth. (A–D) Photographs at 1 year (A), 
birth (B), right foot (C), and left foot (D) of 
LR11-082 (p.Gly106Val) showing diffuse and 
asymmetric body overgrowth, diffuse capillary 
malformations, bilateral syndactyly of second, 
third, and fourth toes, and joint hypermobility. 
(E–G) Photograph of the body (E and F) and 
left foot (G) of LR12-070 (Glu453Lys) showing 
asymmetric overgrowth, capillary malforma-
tions with midline delineation, and postsurgi-
cal changes after resection of the second toe 
due to severe macrodactyly. (H and I) Facial 
photographs of patient LR12-183 (p.Glu542Lys) 
showing multiple epidermal nevi. (J and K) Pho-
tographs of LR12-172 (p.His1047Arg) showing 
macrodactyly of the left hand.
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tional information on a previously reported patient 
(LR12-033) (16, 36) who demonstrates features of  
both dysplastic megalencephaly (effectively bilateral 
hemimegalencephaly) and CLOVES syndrome, mak-
ing her only the second reported child with this severe 
combination. She had severe asymmetric overgrowth, 
diffuse soft tissue swelling consistent with lymphede-
ma, asymmetric head, severe hypotonia, and possible 
right optic nerve hypoplasia (Supplemental Figure 5).
Constitutional PIK3CA mutations. Ten individuals in our cohort harbored constitutional (or apparently 
constitutional) mutations of  PIK3CA that were detectable in peripheral samples (blood or saliva) at AAPs 
ranging from 35%–60% (LR14-323, LR01-060, LR15-076, LR13-036, LR14-278, LR14-358, LR13-048, 
LR15-227, LR12-330, LR15-246, and LR12-340). Interestingly, seven of  these individuals had features of  
MCAP. However, three had diffuse brain or body overgrowth without segmental or patchy manifestations. 
Patient LR15-076 had diffuse megalencephaly, a small patent foramen ovale, and pectus excavatum defor-
mity. Patient LR13-036 had a unique constellation of  features including megalencephaly with rhizomelic 
shortening of  the extremities, polydactyly, complex cardiac defects (left-sided aortic arch, ventricular septal 
defect, atrial dilatation), recurrent hypoglycemia, omphalocele, organomegaly, laryngeal stenosis, and recur-
rent infections, partially overlapping with Beckwith-Wiedemann syndrome. Patient LR12-340 had somatic 
asymmetry, was tall for age, with bilateral 2-3 toe syndactyly, but lacked megalencephaly and vascular anom-
alies. Mutations in five of  these individuals were detected by clinical WES. These PIK3CA mutations were 
detected in blood at standard coverage (20× to 30×), suggesting constitutional mutations. Of note, blood-
derived DNA was not available for analysis on four of  these individuals (LR12-340, LR01-060, LR11-200, 
and LR12-330). Therefore, the possibility of  mosaicism cannot be excluded in these patients.
Discussion
Classification of  PIK3CA-associated developmental phenotypes. GOF mutations of  PIK3CA have been associated 
with a wide spectrum of  pediatric phenotypes (Figure 6). The original and best known of  these is KTS, 
which was first defined more than a century ago based on the now classic triad of  capillary malformation, 
venous varicosities, and limb hypertrophy (37–39). However, published photographs of  KTS vary consid-
erably in appearance. Therefore, it appears that KTS is often used as an umbrella term for any disorder 
with vascular malformation and overgrowth. Several recently described syndromes appear to be more spe-
cific designations, and we have predominantly used these in analyzing our phenotypic data. CLOVES is 
the most severe KTS-like disorder. In practice, most patients with CLOVES have all of  the anomalies in 
the mnemonic (above), dramatic postnatal progression of  the segmental overgrowth and lipomatosis, and 
other abnormalities (19, 40, 41). A subset of  patients with most but not all of  the features of  CLOVES has 
been designated as fibroadipose overgrowth/hemihyperplasia-multiple lipomatosis, but the criteria used to 
Figure 5. Brain MRI images of PIK3CA mutation–positive 
patients. (A and B) LR11-082. T1-weighted mid-sagittal 
(A) and T2-weighted axial (B) image at age 6 months 
showing a large cerebellum, crowded posterior fossa with 
cerebellar tonsillar ectopia, and a relatively normal cortical 
gyral pattern (arrowhead). (C) LR12-184. T1-weighted mid-
sagittal image showing marked cerebellar tonsillar ectopia 
(arrowhead). (D–H) LR12-183. T1-weighted mid-sagittal (D), 
T2-weighted axial (E and G), and coronal (F) images show-
ing diffuse cortical dysplasia, partial agenesis of the corpus 
callosum, dysplasia/hypoplasia of the cerebellar vermis 
and hemispheres, diffuse dysmyelination, abnormal high 
T2 signal intensities in the red nuclei and thalami bilater-
ally (red arrows in E and F), and a very large tectum (red 
arrow in D). (H and I) LR13-197. T1-weighted mid-sagittal 
(H) and T2-weighted axial (I) images showing bilateral 
cortical dysplasia, hippocampal dysplasia, white matter 
dysmyelination, and bilaterally dysplastic ventricles. There 
is mild cerebellar tonsillar ectopia (arrow in H).
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separate them are unclear (10, 21). Capillary malformation with overgrowth (CMO) is a recently defined 
clinical entity characterized by extensive, diffuse, reticulate capillary malformations and variable hypertro-
phy without major complications (42). The phenotype is much less severe than CLOVES, although some 
patients with apparent CMO in infancy go on to develop lipomatosis at older ages. Several other relatively 
mild phenotypes that overlap with CMO have also been described, including the “girth” and “RCM” types 
of  vascular malformations with overgrowth (43). MCAP is characterized by symmetric or only mildly asym-
metric brain overgrowth (megalencephaly) and cutaneous vascular malformations (predominantly capillary 
malformations), with variable malformations of  cortical development (polymicrogyria), body overgrowth, 
digital anomalies (syndactyly and less often polydactyly), and connective tissue laxity (31, 32, 44, 45).
Beyond these multisystem disorders, mosaic mutations of  PIK3CA have recently been identified in 
localized or focal forms of  overgrowth with dysplasia including epidermal nevi (17), isolated macrodactyly 
(22), infiltrating lipomatosis (25, 46), isolated lymphatic malformations (28), and, most recently, venous 
malformations (29). Further, several patients with focal brain involvement, including dysplastic megalen-
cephaly (DMEG), hemimegalencephaly (HMEG), and focal cortical dysplasia (FCD) have been identified 
as well (20, 27, 36). These disorders have been associated with variable but often low levels of  mutations 
in affected tissues, and very low or undetectable levels in apparently unaffected tissues, such as peripheral 
blood lymphocytes. Finally, several patients have been reported with constitutional mutations of  PIK3CA 
associated with isolated megalencephaly or unspecified “Cowden-like” features (30, 47).
Several recent reviews have presented PIK3CA-associated phenotypes as essentially a single broad 
spectrum (10). However, the original phenotype descriptions and the molecular data presented here argue 
otherwise. We view the differences between the clinical presentation as consistent and recognizable, based 
on our observations in the largest series of  mosaic mutations of  a single gene underlying developmental 
disorders reported to date. We propose that the PIK3CA-associated spectrum of  disorders should serve 
as a paradigm for mosaic disorders. The clinical differences between MCAP and CLOVES (including 
CLOVES-DMEG) syndromes are summarized in Table 5. In MCAP, head and brain overgrowth are often 
the presenting signs, while body overgrowth at birth is mild (+1 to +2 SD) with stature normalizing by ~8 
years (32). The cutaneous vascular malformation typically presents as congenital livedo reticularis (38). 
The head and body overgrowth and livedo reticularis are most often diffuse with subtle asymmetry. About 
60%–70% of  patients have a cortical malformation, with imaging and clinical features consistent with bilat-
Figure 6. The PI3K-AKT-MTOR–related developmental brain disorders spectrum. Diagram showing the PI3K-AKT-MTOR pathway highlighting genes 
associated with developmental brain disorders including PIK3CA, PIK3R2, PTEN, AKT3, MTOR, CCND2, DEPDC5, NPRL2, and NPRL3 (shown in blue), as well 
as TSC1 and TSC2 genes (shown in red).
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eral perisylvian polymicrogyria (31, 32). Lipomas, lymphatic malformations, and macrodactyly occur, but 
are typically uncommon, limited in size, do not progress, and rarely require surgical intervention. Epider-
mal nevi are rare. In CLOVES, on the other hand, head and brain size are typically normal, although rare 
patients with combined CLOVES and DMEG have been observed (i.e., LR12-033). The cutaneous vascu-
lar malformations have a variable presentation from a classic port-wine stain appearance to pale pink or red 
capillary malformations. Body overgrowth including macrodactyly, lipomas, and lymphatic malformations 
are segmental and often severe with rapid postnatal progression. Epidermal nevi are common (19, 41).
Our data also show that the mutational spectrum of these disorders is different. The mutations associ-
ated with MCAP syndrome in particular are distinct from other PIK3CA-related overgrowth disorders. The 
mutational spectrum in MCAP is broad, with greater than 20 milder GOF mutations seen across the entire 
gene, whereas most mutations seen in CLOVES, KTS, DMEG, and other focal forms of overgrowth (such as 
isolated macrodactyly) are more often associated with the cancer hotspot mutations. Given this wide muta-
tional spectrum, we recommend using a broad molecular strategy that tests the entire PIK3CA coding sequence, 
rather than targeted mutation screening of common mutations in individuals with similar phenotypes. Several 
individuals lacked megalencephaly, and had variable somatic overgrowth with vascular malformations, fur-
ther expanding the spectrum of PIK3CA-related overgrowth. Therefore, the molecular data on PIK3CA-related 
overgrowth disorders to date show that they comprise a discontinuous spectrum of disorders that correlate well 
with the severity (strength of GOF) and distribution of the mutation, rather than a single continuous spectrum.
Diagnosis of mosaicism in developmental disorders
Genetic disorders caused by postzygotic (or mosaic) variants are increasingly recognized with the advent of  
deep NGS methods. The contribution of mosaic variation to developmental brain disorders has also been 
increasingly appreciated in various segmental disorders including HMEG, FCD, and, more recently, bilateral 
perisylvian polymicrogyria (16, 20, 27, 36, 48–51). However, detecting low-frequency mosaic variants in clini-
cal practice remains challenging for several reasons. First, the availability of nonblood tissue sources (such as 
affected skin or brain) may be limited. Second, available diagnostic testing methods used in clinical diagnostic 
labs (such as Sanger sequencing or standard-depth NGS) are insufficiently sensitive to detect mosaic variation. 
We therefore sought to address these issues by sequencing large cohorts of samples from individuals with 
overgrowth in general, and MCAP in particular, using 2 independent deep-targeted NGS methods that utilize 
MIPs and amplicon deep sequencing. These methods have been particularly demonstrated to be effective for 
detecting low-frequency variants (14, 15). When combined with single-molecule tagging with multiplex target-
ed sequencing (smMIPs), the MIP method further increases the sensitivity for the detection of low-frequency 
variants, as single-molecule tagging marks sequences derived from a common progenitor molecule. Our results 
also challenge the current clinical practice of using blood-derived DNA for almost all clinical genetic testing. 
Our study suggests that a change in clinical practice is indicated for disorders suspected to be associated with 
somatic mosaicism, such as those involving asymmetry or other segmental or focal presentation, i.e., as a large 
majority of vascular malformations, overgrowth, cutaneous pigmentary abnormalities, noncancerous dyspla-
sia (i.e., epidermal nevi).
Table 5. Comparison of intermediate and hotspot PIK3CA gain-of-function phenotypes
Feature/Group Less-activating mutations (MCAP) Hotspot mutations (CLOVES, DMEG)
Brain size Large Normal
Malformations of cortical development Normal or PMG DMEG-HMEG-FCD type 2
Skin capillary malformation Congenital livedo reticularis Port-wine stain
Skin pigmented nevus (none) Epidermal nevi
Body overgrowth congenital Diffuse, mild asymmetry Segmental and severe
Body overgrowth postnatal No Severe
Lipomas-lipomatosis Few and small Many large and grow
Lymphatic malformation Rare and small Frequent and large
Abbreviations: CLOVES, congenital lipomatous truncal overgrowth, vascular anomalies, epidermal nevi and skeletal/spinal anomalies; DMEG, 
dysplastic megalencephaly; FCD, focal cortical dysplasia;HMEG, hemimegalencephaly; MCAP, megalencephaly-capillary malformation syndrome; 
PMG, polymicrogyria. 
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Summary
Our data expand on the molecular and phenotypic spectrum of  PIK3CA-related developmental disorders. 
First, we show that the mutational spectrum in children with MCAP is broader than other PIK3CA-related 
overgrowth disorders. Further, we report on several atypical or expanded phenotypes, including children 
with body overgrowth without megalencephaly, that appear milder than CLOVES and other severe forms 
of  somatic overgrowth. Finally, we report on constitutional mutations of  PIK3CA in a subset of  children, 
some of  whom have milder features such as diffuse megalencephaly with intellectual disability, similar to 
the PTEN-related disorders (52). Based on our data and review of  the literature, we propose a molecularly 
based classification of  these disorders. Overall, our molecular studies in this large series show that pheno-
types of  mosaic disorders are impacted not only by tissue distribution and levels of  mosaicism, but also 
by class (strength of  activation) of  mutation. Our series helps inform best clinical practices for diagnostic 
methods and tissues to sample in mosaic disorders broadly.
Methods
Sample processing. Genomic DNA was extracted from blood using the Puregene Blood Core Kit (QIA-
GEN), saliva using the Oragene Saliva Kit (DNA Genotek), buccal cells from Oragene Saliva Kits follow-
ing centrifugation, and skin fibroblasts following a skin biopsy. Fibroblasts were grown in DMEM/F12 
with glutamine, supplemented with 10% FBS and 1% PenStrep (all three from Gibco). DNA was extracted 
both directly and from fibroblasts after digesting with proteinase K in Cell Lysis Buffer (both QIAGEN) 
using prepIT.L2P (DNA Genotek) and ethanol precipitation. Lymphocytes were separated from whole 
blood using Ficoll and subsequently transformed to lymphoblastoid (LB) cell lines using Epstein-Barr virus 
(EBV) in RPMI 1640 media with glutamine, supplemented with 10% FBS and 1% PenStrep (all three from 
Gibco). Genomic DNA was then extracted using a Puregene Blood Core Kit.
Multiplex targeted sequencing using smMIPs. We designed a pool of  48 smMIP oligonucleotide probes 
targeting the coding sequences of  PIK3CA. smMIPs tiled across a total of  3,340 bp of  genomic sequence, 
including 100% of  the 2,202 coding bp of  PIK3CA. One hundred–nanogram capture reactions were 
performed in parallel. Massively parallel sequencing was performed with the Illumina HiSeq. Variant 
analysis was performed using our previously published pipeline including MIPgen and PEAR version 
0.8.1 (48, 53). All missense, nonsense, and splice site variants seen at a frequency of  less than 1% in 
public databases, in 2 or more capture events were retained for analysis. Our MIP capture method has 
been previously published (48).
Amplicon sequencing. Amplicon sequencing was performed using previously published methods (48). 
We performed locus-specific amplification of  genomic DNA followed by GS Junior sequencing (Roche). 
We designed fusion primers containing genome-specific sequences along with distinct multiplex identifier 
sequences (used to differentiate samples being run together on the same plate) and sequencing adapters, 
to generate amplicons ranging in size from 290 to 310 bp, using Primer3Plus software. Primer sequences 
are provided in Supplemental Table 4. Small DNA fragments were removed with Agencourt AMPure 
XP (Beckman Coulter) according to the manufacturer’s protocol. All amplicons were quantified with 
the Quant-iT PicoGreen dsDNA reagent (Life Technologies), pooled at equimolar ratios, amplified by 
emulsion PCR using the GS Junior Titanium emPCR kit (Lib-A kit, Roche Applied Science), and pyrose-
quenced in the sense and antisense strands on a GS Junior sequencer following the manufacturers’ instruc-
tions. Data were analyzed using GS Amplicon Variant Analyzer version 3.0 software.
WES. WES produced 18.2 GB of  sequencing data per proband. Mean coverage of  captured regions 
was ~250× for proband samples, with ~99.17% covered with at least 10× coverage, an average of  89.82% 
of  base call quality of  Q30 or greater, and an overall average mean quality score of  Q35. WES was per-
formed using previously published methods (54).
Targeted NGS. This assay sequenced all exons of  PIK3CA, and average coverage ranged from 320 to 
greater than 1,000 sequencing reads per bp. Genomic regions were captured using biotinylated RNA oli-
gonucleotides (SureSelect), prepared in paired-end libraries with ~200-bp insert size, and sequenced on an 
Illumina HiSeq2500 instrument with 100-bp read lengths, in a modification of  a previously reported pipeline 
(55). Large deletions and duplications were detected by this panel using previously published methods (56).
Statistics. We completed a pairwise comparison of mean values for alternative allele percentages in the three 
tissue types, where a 2-tailed t test gave P values of 0.0352, 0.0365, and 0.566 for blood versus saliva, blood 
versus skin, and saliva versus skin, respectively. A P value less than 0.05 was considered statistically significant.
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